

Review

Overview of Atopic Dermatitis in Different Ethnic Groups

Andrea Chiricozzi ^{1,2,*} , Martina Maurelli ³ , Laura Calabrese ^{1,2} , Ketty Peris ^{1,2} and Giampiero Girolomoni ³ 

¹ UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli-IRCCS, 00168 Rome, Italy

² Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy

³ Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37126 Verona, Italy

* Correspondence: chiricozziandrea@gmail.com; Tel.: +39-06-30154227

Abstract: Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a high prevalence worldwide, including countries from Asia, Africa, and Latin America, and in different ethnic groups. In recent years, more attention has been placed on the heterogeneity of AD associated with multiple factors, including a patient's ethnic background, resulting in an increasing body of clinical, genetic, epidemiologic, and immune-phenotypic evidence that delineates differences in AD among racial groups. Filaggrin (FLG) mutations, the strongest genetic risk factor for the development of AD, are detected in up to 50% of European and 27% of Asian AD patients, but very rarely in Africans. Th2 hyperactivation is a common attribute of all ethnic groups, though the Asian endotype of AD is also characterized by an increased Th17-mediated signal, whereas African Americans show a strong Th2/Th22 signature and an absence of Th1/Th17 skewing. In addition, the ethnic heterogeneity of AD may hold important therapeutic implications as a patient's genetic predisposition may affect treatment response and, thereby, a tailored strategy that better targets the dominant immunologic pathways in each ethnic subgroup may be envisaged. Nevertheless, white patients with AD represent the largest ethnicity enrolled and tested in clinical trials and the most treated in a real-world setting, limiting investigations about safety and efficacy across different ethnicities. The purpose of this review is to describe the heterogeneity in the pathophysiology of AD across ethnicities and its potential therapeutic implications.

Keywords: atopic eczema; dermatitis; allergy; itch; skin disease; treatment; prevention; epidemiology; ethnic differences; cellular; molecular; immunological; physiological therapeutic



Citation: Chiricozzi, A.; Maurelli, M.; Calabrese, L.; Peris, K.; Girolomoni, G. Overview of Atopic Dermatitis in Different Ethnic Groups. *J. Clin. Med.* **2023**, *12*, 2701. <https://doi.org/10.3390/jcm12072701>

Academic Editor: Mohsen Afarideh

Received: 25 February 2023

Revised: 16 March 2023

Accepted: 3 April 2023

Published: 4 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Atopic dermatitis (AD) is one of the most common immune-mediated skin disorders, with a chronic-relapsing course and a multifactorial pathogenesis [1]. The prevalence of AD is very high worldwide, including countries from Asia, Africa, and Latin America, across different ethnic groups, as well as across different ages [2].

The disease is clinically characterized by itchy eczematous lesions primarily involving flexural areas and the face, neck, and distal extremities, and it might precede other non-cutaneous atopic manifestations, such as asthma and allergic rhinitis (AR), priming the so-called “atopic march” [3].

Unlike other inflammatory skin diseases, AD shows a certain degree of clinical heterogeneity, leading researchers to consider this condition as a spectrum instead of a single entity. For this reason, in recent years, several efforts have been made to characterize disease subtypes according to different parameters, such as phenotypes, skin barrier status, IgE levels, age, gender, and ethnicity [4]. Moreover, different endotypes across different age groups and ethnicities and according to IgE levels and filaggrin mutation status have been identified through specific molecular signatures [5].

Depending on the patient's racial background, AD seems to show different clinical, genetic, and immunopathogenic features [6]. Nevertheless, Caucasian patients with AD still represent the most studied ethnic group, leading to uncertainty in fully defining differences and similarities in disease pathophysiology across different ethnicities.

This review aimed to explore the current insights on AD heterogeneity depending on patient ethnicity and to analyze the possible therapeutic implications of these pathophysiological differences.

2. Clinical Features

Several AD phenotypes have been described according to lesion distribution (e.g., flexural, head and neck, periorificial) or the predominant clinical feature, such as nummular eczema, prurigo nodularis, lichenified dermatitis, or follicular/papular dermatitis [7]. Interestingly, some differences in the clinical manifestations of AD exist among ethnic groups, which may pose diagnostic challenges. The clinical heterogeneity of AD is oftentimes the result of differences in the distribution and pigmentation of the lesions [8]. Asian individuals typically present lesions with more defined borders, sometimes closely resembling psoriasis plaques, as well as more scaling and lichenification, in comparison to white AD patients [9,10]. Conversely, African AD patients present with a predominant extensor involvement [11] and sometimes with perifollicular accentuation and distinct papules on the extensor surfaces and on the trunk [12,13]. Furthermore, in darker skin types exclusively, a lichen-planus-like presentation of AD has been described [14].

Because of the almost complete absence of erythema in dark skin types, oedema, warmth of the skin, or overlying scale may help dermatologists in identifying the presence of erythema. Furthermore, many scoring systems in clinical practice, such as the eczema area and severity index (EASI) [15] or the scoring AD (SCORAD) [16], rely on erythema to assess the disease's severity and thus have the tendency to underestimate it in darker skin types [17]. In addition, patients with darker skin types, more frequently than white patients, exhibit xerosis, hyperlinearity of the palms, Dennie–Morgan lines, periorbital darkening, lichenification, and prurigo nodularis [11].

Finally, the risk of developing post-inflammatory hyper- or hypo-pigmentation is more common in dark skin [18].

3. Genetic Variability across Ethnic Groups

Similarly to other chronic inflammatory dermatoses, a genetic predisposition based on a polygenic background is associated with the development of AD. Certain genes have been implicated in the predisposition to AD, in particular those related to the skin barrier function, those involved in Th2 immune responses, and those implicated in the vitamin D metabolism and the synthesis of its receptors [19].

An attempt to study ethnic differences in AD from a genetic perspective, seeking to identify ethnic-specific genes, has been recently conducted in African, Asian, and Hispanic populations through genome-wide association studies (GWAS) [20–26].

Loss-of-function mutations (LOF) of the structural protein filaggrin represent the strongest genetic risk factor for the development of AD and are detected in up to 50% of European and 27% of Asian AD patients [27–29]. The filaggrin precursor pro-filaggrin is encoded by the *FLG* gene, located in the epidermal differentiation complex (EDC) on chromosome 1q23.3. Filaggrin deficiency is a major determinant of defective barrier function [30], and it is associated with (i) a disrupted keratinocyte differentiation, (ii) an impaired corneocyte integrity and cohesion, (iii) an altered tight junction formation, (iv) a decreased water retention, (v) an abnormal lipid formation, as well as (vi) an enhanced susceptibility to cutaneous infections [31]. Patients carrying LOF mutations in the *FLG* gene exhibit a more severe phenotype of AD, with a more persistent course, a higher risk of skin infections and allergic sensitization, as well as a major impairment of the immune system compared to patients with wild-type *FLG* [32,33].

Interestingly, filaggrin LOF mutations show a certain population specificity. The first two characterized mutations, R501X and 2282del4 [34], as well as S3247X and R2447X, have been extensively studied and are present in 7–10% of the white European population, whereas they are absent in Asian populations, which have a different spectrum of *FLG* variants [27]. Conversely, studies failed to detect common *FLG* LOF mutations in people of African ancestry with AD, although decreased levels of filaggrin have been reported in the skin of these patients [35,36]. Interestingly, no association between *FLG* LOF and AD have been found in African populations (Ethiopian) so far [37], whereas a relationship has been described in African Americans, probably due to genetic admixture [33,38]. Overall, *FLG* LOF mutations are six times less common in subjects of African descent than in people of European and Asian descent, suggesting a minor contribution to AD development [33].

The absence of *FLG* gene mutations in African people has prompted further genetic investigations in patients of this ethnicity. Results from whole-exome sequencing (WES) analysis in Ethiopian AD patients revealed an association between LOF mutations in the *FLG2* gene and the persistence of AD [39]. The *FLG2* gene is located within the EDC, sharing with *FLG* a similar molecular structure and biological functions [40,41]. Similarly, another study based on a whole exome analysis demonstrated that *FLG2* mutations were associated with a more persistent AD in an African American cohort [42]. On the contrary, studies conducted on European subjects did not reveal any association between the *FLG2* missense variant (rs16833974) and AD [43,44].

Beyond the EDC, variants in genes encoding for proteins involved in maintaining epidermal homeostasis have been described in specific ethnicities. For example, mutations in claudin 1 (*CLDN1*) gene, encoding for a structural protein of the tight junctions, have been related to the early onset of AD in Ethiopian patients, and it may be involved in the susceptibility of AD in this population [45]. In addition, some studies detected an association between LOF mutations in *SPINK5*, encoding for a serine-protease inhibitor involved in epidermal homeostasis and classically associated with both an autosomal recessive congenital ichthyosis and AD in East Asian populations [46–49].

The second class of genes implicated in AD susceptibility is related to the innate and adaptive immunity and, in particular, to the Th2 pathway that is central to AD pathogenesis.

Several studies described a correlation between polymorphisms in *IL-4*, *IL-13*, *IL-31*, *IL-4RA*, and *IL-31RA1* genes, all belonging to the Th2 pathway, and an increased risk of developing AD [50–55]. Similar to those involved in the epidermal function, genes related to the immune response characterizing AD showed some differences across ethnic groups.

In detail, polymorphisms of *IL-4* and *IL13/IL-13RA1* have been associated with an AD predisposition in Japanese, Korean, and Chinese populations [52,54,56,57], while AD susceptibility was significantly associated with *IL4RA* and *STAT6* polymorphisms in Egyptian children [54]. One specific polymorphism (Q576R) of the *IL4R α* gene, associated with AD severity in murine models, has been found to be over-represented in the African American population [58,59].

Moreover, many other genes encoding molecules that contribute to AD pathogenesis at different levels, such as *STAT6*, thymic stromal lymphopoietin (*TSLP*), *IL7R*, *TSLPR*, interferon regulatory factor 2 (*IRF2*), toll-like receptor 2 (*TLR2*), Fc ϵ RI α (*FCER1A*), and β -Defensin (*DEFB1*), have been found to be implicated in AD susceptibility in different ethnic groups [60–62]. For example, polymorphisms in the *IRF2* gene were associated with AD in European Americans (rs793814 and rs3756094) and in African Americans (rs3775572) [63], and a specific *TSLP* variant (rs1898671) has been related to less persistent AD in white and African Americans [64].

In Japan, a *TLR2* variant has been proposed as a genetic predictor of AD severity, while *FCER1A* polymorphisms have been related to significantly higher IgE serum levels in AD patients [65,66].

Variants in the *DEFB1* gene, encoding a small antimicrobial peptide mainly expressed in the epidermis and promoting host defense against pathogens, have been related to an increased risk of AD in Brazilian, Mexican, and Korean populations [67–69]. Notably,

variants in genes encoding IL-12 and its receptor have been reported as susceptibility genes in Korean AD patients [70].

4. Pathogenesis

The pathogenesis of AD is characterized by a complex interplay between genetic and environmental factors contributing to epidermal barrier disruption, commensal skin microbiota dysbiosis, and alterations in immune responses, causing disease occurrence and/or exacerbation [3].

The contribution of the skin microbiota in AD is widely recognized [71]. In more than 90% of AD patients, skin lesions are colonized with *Staphylococcus Aureus*, and the density of the bacterium is associated with AD severity [72,73]. Similarly, AD skin during flares is characterized by a poor heterogeneity of the skin microbiota's composition, favoring the predominance of *S. Aureus* [74]. Furthermore, *S. Aureus* skin colonization in infancy often precedes the diagnosis of AD [75], suggesting that it may be also a disease trigger. Differences in *S. Aureus* colonization and variability in the prevalence of specific bacterial virulence factors between ethnic groups have been reported and may be partially responsible for the molecular and phenotypic heterogeneity of AD across ethnicities, likely contributing to a more mixed immune dysregulation that involves not only type 2 inflammatory cells but also Th22 and Th17 cells [76]. Other environmental factors such as tobacco smoking habits, sun exposure, and psychosocial factors might negatively impact on disease onset or severity and they might differ across ethnicities. Racial and ethnic disparities have been detected in the use of tobacco [77]. Similarly, sun exposure differs based on ethnicity and cultural factors in subjects living in the same country [78]. Beyond chronic stressors that may impact any individual, psychosocial factors represented by racism, discrimination, and acculturative stress (anxiety or tension related to efforts to adapt to the values of dominant culture within a society) are uniquely frequent among ethnic minorities [79], with African American adults living below the poverty line being twice as likely to experience psychological distress and to not receive medical care [80].

Immune Mechanisms Involved in AD Pathogenesis

The current pathogenic model of AD is centered on the activation of type 2 immune cells such as T helper (h)2 cells, T follicular helper (Tfh) cells, innate lymphoid cells 2 (ILC2), T cytotoxic (c)2 cells, eosinophils, mast cells, and basophils, with contributions from other pathways to different extents, including Th/Tc22, Th9, Th1, Th/Tc21, and Th17 [70,81,82].

During the initial phases of the pathogenic cascade, keratinocytes are activated by the excessive exposure to allergens, irritants, and microbial antigens due to an epidermal barrier disruption, causing the release of chemokines such as thymus and activation-regulated chemokine (TARC, known as CCL17) [81], macrophage-derived chemokines (MDC or CCL22) [82,83], and innate immune cytokines, such as IL-1 β , IL-33, and thymic stromal lymphopoietin (TSLP), with subsequent activation of ILC2s and Th2 cell-mediated immune responses [84]. Particularly, TSLP-activated dendritic cells express OX40 ligand (OX40L) which, upon binding to its receptor OX40, induces Th2 differentiation of naive T cells, resulting in the production of Th2 cytokines (IL-4, IL-5, IL-13, and IL-31) [85]. Moreover, ILC2s represent a relevant source of IL-5 and IL-13, thus contributing to the creation of a type 2 inflammatory cytokine milieu [86].

While the type 2 signal dominates acute and chronic phases of the disease and is constantly elevated in AD in all ethnic groups, an upregulation of other immune pathways can occur differently across ethnicities [87,88].

The Asian endotype of AD is typically characterized by a strong Th17 signature, as well as by peculiar clinical and histological features [89]. Comparing the gene expression profile of European American, Japanese, and Korean AD patients, and including as a control groups patients with psoriasis and healthy controls, the presence of a strong Th2 activation was detected in both Asian and European American AD patients but not in psoriasis patients. Conversely, a significantly higher expression of Th17 and Th22 (IL17A,

IL19, S100A12, IL-22) and lower expression of Th1 genes (CXCL9, CXCL10, IFNG) was found in Asian AD patients [10]. In addition, Asian AD skin showed greater acanthosis, higher Ki67 counts, and frequent parakeratosis, prompting the conclusion that the Asian AD endotype presents overlapping features with European AD and psoriasis [10].

Another study investigating the molecular profile of AD has been conducted on Chinese AD patients in comparison with European Americans, psoriatic patients, and ethnicity-matched healthy controls. The gene expression analysis showed similar results in Chinese AD patients compared with those observed in Japanese and Korean patients, suggesting a consistent Th17/Th2 or blended AD–psoriasis endotype across all Asian AD patients [90].

Along these lines, an upregulation of the serum Th2 markers was found in both Asian and European American AD patients, together with a lower expression of Th1 markers (IFN γ , CCL2, CCL3, CCL4) and increased Th22 activation in Asian patients compared to European American. In contrast to the gene expression signature detected in the skin, serum levels of Th17 markers were not increased in Asian patients [91]. Similarly, a characterization of the immunophenotype of AD in African Americans was recently carried out through gene expression analysis. The results from this study revealed a strong Th2/Th22-skewing in African American AD patients, with both Th2 and Th22 markers correlating significantly with disease severity, and concomitantly, an attenuation of the Th1 and Th17 axes compared to European Americans was observed. In addition, the skin of African American AD patients had peculiar barrier changes such as a lower filaggrin decrease but greater loricrin reduction that differed from European AD subjects [92].

5. Therapeutic Implications in Different Ethnic Subgroups

Currently, therapeutic approaches and recommendations for AD treatment do not differ across ethnic groups, nor is ethnicity taken into consideration in current European or American guidelines or recommendations [93–95]. Indeed, limited investigations on the effects of therapeutic agents on AD in different ethnic groups have been performed so far.

From daily clinical practice, it can be inferred that topical steroids are overall effective for all skin types. However, they should be used with caution as they frequently induce or worsen hypopigmentation in darker skin types [96].

A study on the use of pimecrolimus cream 1% on AD patients of different origins showed that ethnicity had no impact on treatment outcomes [97]. In addition, a pooled data analysis about the efficacy and safety data of tacrolimus ointment compared outcomes obtained in eight Asian countries with outcomes obtained in the United States, Europe, and Japan, reporting similar results [98].

For moderate-to-severe AD, phototherapy is a possible therapeutic option, especially narrow band UVB (NB-UVB). In one study conducted in Singapore, both NB-UVB- and UVA/NB-UVB-based phototherapy were effective in the treatment of AD in Asian children [99]. Of note, the use of phototherapy in darker skin types necessitates some special considerations: NB-UVB has been shown to require higher doses in darker skin [100,101], while UVA1 phototherapy seems to be equally effective in Fitzpatrick I–V skin phototypes without any dose adjustment [102].

Concerning systemic therapies, differences in terms of efficacy and safety profiles across ethnicities may depend on several factors, such as a different metabolism of the drug, which may ultimately affect its bioavailability. For example, black individuals have a 20–50% lower bioavailability of cyclosporine than white individuals, thus requiring higher doses of the drug [103]. The use of methotrexate, an antifolate metabolite acting as an immunosuppressive agent, has been associated with a higher risk of alopecia in black patients [103]. Furthermore, azathioprine, another immunosuppressive agent that requires the activity of the enzyme thiopurine methyltransferase (TPMT) for its metabolism, may cause severe toxicity in black patients at normal dosages, since deficiency of TPMT is prevalent in this population [103].

Dupilumab, a fully human monoclonal antibody blocking the shared IL4R α subunit, binding to both IL-13 and IL-4, was the first biologic agent approved for the treatment of moderate-to-severe AD [104]. Phase III trials testing dupilumab included 20–27% Asian and 5–7% Black patients and suggested a comparable efficacy in diverse populations [105–107]. Recently, a post-hoc analysis from three phase III trials (LIBERTY AD SOLO 1, SOLO 2 and CHRONOS) assessed the efficacy and safety of dupilumab vs. a placebo across racial subgroups (White, Asian, Black/African American) and demonstrated that, independently of ethnicity, dupilumab resulted effective in improving AD and was deemed safe, with a favorable benefit–risk profile [108]. The identification of a specific polymorphism (Q576R) of the *IL4R α* gene, overrepresented in the African American population, provides a further rationale for the great efficacy of dupilumab in this subgroup of AD patients [59].

Furthermore, a cross-sectional study assessing the patient burden and the impact on quality of life of AD in the U.S. population has shown that the effectiveness of dupilumab in improving the quality of life in patients was similar amongst various racial groups (white, Asian, black/African American) [96].

Novel biologic agents and small molecules, such as tralokinumab [109], upadacitinib [110], baricitinib [99], and abrocitinib [111], have been recently approved, and many others are currently under investigation for the treatment of moderate-to-severe AD.

Tralokinumab is a first-in-class IgG4 monoclonal antibody that specifically binds with high affinity to IL-13. Results from phase III clinical trials have demonstrated a substantial improvement in the severity and symptoms of AD after tralokinumab administration [112,113]. Recently, a sub-analysis of tralokinumab phase III trials (ECZTRA 1, 2, and 3) was conducted to evaluate its efficacy and safety in a North American population vs. a non-North American population. Of note, approximately 30–52% of patients in the North American population had skin of color, versus 5–25% in the non-North American population. The results of this post-hoc analysis of three large phase III trials displayed the safety and efficacy of tralokinumab regardless of the ethnicity [114].

6. Discussion

In recent years, a great interest in deciphering the clinical and molecular heterogeneity of AD across ethnicities has prompted the development of clinical, genetic, epidemiologic, and molecular studies analyzing AD in different ethnic groups, in an attempt to characterize the disease's subtypes. Although the similarities among different ethnic groups are by far larger than the differences in all disease aspects, a growing body of evidence suggests race-specific alterations in the epidermal structure, as well as differences in the magnitude of upregulation related to certain immune pathways. In general, healthy skin from European, African, and Asian populations might exhibit significant molecular differences. For instance, the higher rate of *FLG* mutations in European populations could be attributed to evolutionary pressures as *FLG* deficiency may have provided enhanced immunity against infections, and therefore protection during European pandemics in past centuries [115], and it may have ensured greater vitamin D synthesis in the skin, conferring an evolutionary advantage at high latitudes [116].

Interestingly, even the atopic march, which encompasses food allergy, asthma, allergic rhinitis, and conjunctivitis after AD, may show a certain racial variability [117]. A longitudinal study indicated wide differences in allergic comorbid trajectories between black and white children with AD. Black children had higher risk of asthma and lower risk of allergic rhinitis and food allergy, while white children were most likely to progress to allergic rhinitis and food allergy, despite a lower asthma risk. These differences may be partly explained by ancestral genetic variabilities but also by different exposure to various race-specific environmental risk factors [118]. Overall, the presence of extracutaneous atopic manifestations suggest a prominent role of the type 2 inflammation in all ethnic groups. However, the contribution of other immune pathways led to the identification of endotypes corresponding to specific phenotypes that, so far, has been poorly defined, as demonstrated by the relatively high upregulation of the Th17 signal in Asian AD compared

with European AD skin, which could explain the predominance of well-demarcated, psoriasisiform lesions in Asian patients compared to European ones but cannot explain why the inhibition of IL-17A failed to demonstrate clinical, histopathological, and transcriptomic benefits (Figure 1) [106,119].




Figure 1. Main genetic, clinical, and immunological features in AD patients across ethnicities. Predominant genetic features of each subgroup, immune-polarization, and potential therapeutic implications are shown. FLG: Filaggrin; LOF: Loss-of-function; IL: Interleukin; TSLP: Thymic stromal lymphopoietin; IRF2: Interferon regulatory factor 2; TLR2: Toll-like receptor 2; FCER1A: Fcε Receptor1α; DEFB1: B -Defensin 1; SPINK5: Serine Peptidase Inhibitor Kazal Type 5; TCHH: Trichohyalin; TCHHL1: Trichohyalin like 1; CRNN: Cornulin; HRNR: Hornerin; CLDN1: Claudin 1; Th: T helper; JAKi: JAK inhibitors. Created with BioRender.com.

On the contrary, the efficacy of dupilumab first, and tralokinumab more recently, across ethnicities has confirmed the central role of type 2 inflammation in all AD ethnic groups. Notably, transcriptomic studies revealed broader effects of dupilumab in directly suppressing the type 2 inflammatory signal and indirectly down-regulating the Th17/Th22-related signals, partially explaining its efficacy in treating patients belonging to different ethnicities, even in those characterized by a lessened type 2 inflammatory signature [120]. African AD patients show strong Th2 skewing with a high correlation between disease severity and Th2/Th22-related markers as well as IgE serum levels [92]. Therefore, those patients may reasonably benefit the most from the neutralization of IL-22 (by fezakinumab, an anti-IL-22 monoclonal antibody) or a Th2-targeting agent.

Beyond selected cytokine antagonists, novel classes of drugs targeting Janus kinases (JAK) with different selectivity, thus having a “broader” range of action, demonstrated high efficacy in treating AD. The JAK inhibitors, targeting one or more members of the JAK family, can simultaneously inhibit several downstream pathogenic pathways in AD [121]. Their broad suppressive activity may be promising and appealing to provide therapeutic benefit across all ethnicities. No data are currently available on the safety and efficacy profile of JAK inhibitors across ethnicities because non-white patients are still under-represented in AD clinical trials (18% of all patients included are black, 6.9% Asian, and 2% Hispanic), estimating that only 59% of AD clinical trials performed between 2000 and 2009 included

race and ethnicity as a baseline demographic characteristic, and this is a limitation for interpreting data through race [122–124].

7. Conclusions

Differences amongst various ethnicities in terms of clinical phenotypes and their corresponding immune endotypes exist, though they are not fully elucidated.

However, this ethnic heterogeneity of AD may hold important therapeutic implications.

The “one-size-fits-all” therapeutic approach offers results that are not always satisfactory and may not be ideal. Therefore, future investigations could hopefully stratify AD populations more precisely by ethnicity and pave the way for the development of a personalized and tailored approach that better targets the immunologic pathways involved in each ethnic subgroup.

Unfortunately, ethnicity data on most new agents for AD are largely not available, and the inclusion of different ethnic groups in randomized clinical trials, as well as sub-analyses by race, are of great importance and should be strongly encouraged.

Funding: This research received no external funding.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: Dr. Maurelli and Dr. Calabrese declares no conflict of interest. Prof. Girolomoni has received personal fees from AbbVie, Abiogen, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Leo Pharma, Merck Serono, Novartis, Pfizer, Samsung, and Sanofi. Prof. Ketty Peris has served on advisory boards and received honoraria for lectures and/or research grants for Abbvie, Almirall, Lilly, Galderma, Leo Pharma, Pierre Fabre, Novartis, Sanofi, Sun Pharma, and Janssen. Prof. Andrea Chiricozzi has served as an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Almirall, Bristol Myers Squibb, Leo Pharma, Lilly, Janssen, Novartis, Pfizer, and Sanofi Genzyme.

References

- Langan, S.M.; Irvine, A.D.; Weidinger, S. Atopic dermatitis. *Lancet* **2020**, *396*, 345–360. [[CrossRef](#)] [[PubMed](#)]
- Hadi, H.A.; Tarmizi, A.I.; Khalid, K.A.; Gajdacs, M.; Aslam, A.; Jamshed, S. The Epidemiology and Global Burden of Atopic Dermatitis: A Narrative Review. *Life* **2021**, *11*, 936. [[CrossRef](#)] [[PubMed](#)]
- David Boothe, W.; Tarbox, J.A.; Tarbox, M.B. Atopic Dermatitis: Pathophysiology. *Adv. Exp. Med. Biol.* **2017**, *1027*, 21–37. [[CrossRef](#)] [[PubMed](#)]
- Tokura, Y.; Hayano, S. Subtypes of atopic dermatitis: From phenotype to endotype. *Allergol. Int.* **2022**, *71*, 14–24. [[CrossRef](#)] [[PubMed](#)]
- Czarnowicki, T.; He, H.; Krueger, J.G.; Guttman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. *J. Allergy Clin. Immunol.* **2019**, *143*, 1–11. [[CrossRef](#)]
- Brunner, P.M.; Guttman-Yassky, E. Racial differences in atopic dermatitis. *Ann. Allergy Asthma Immunol.* **2019**, *122*, 449–455. [[CrossRef](#)]
- Girolomoni, G.; de Bruin-Weller, M.; Aoki, V.; Kabashima, K.; Deleuran, M.; Puig, L.; Bansal, A.; Rossi, A.B. Nomenclature and clinical phenotypes of atopic dermatitis. *Ther. Adv. Chronic. Dis.* **2021**, *12*, 20406223211002979. [[CrossRef](#)]
- Sachdeva, M.; Joseph, M. Dermatology: How to manage atopic dermatitis in patients with skin of colour. *Drugs Context* **2022**, *11*, 2021-12-1. [[CrossRef](#)]
- Leung, D.Y. Atopic dermatitis: Age and race do matter! *J. Allergy Clin. Immunol.* **2015**, *136*, 1265–1267. [[CrossRef](#)]
- Noda, S.; Suarez-Farinas, M.; Ungar, B.; Kim, S.J.; de Guzman Strong, C.; Xu, H.; Peng, X.; Estrada, Y.D.; Nakajima, S.; Honda, T.; et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. *J. Allergy Clin. Immunol.* **2015**, *136*, 1254–1264. [[CrossRef](#)]
- Vachiramon, V.; Tey, H.L.; Thompson, A.E.; Yosipovitch, G. Atopic dermatitis in African American children: Addressing unmet needs of a common disease. *Pediatr. Dermatol.* **2012**, *29*, 395–402. [[CrossRef](#)]
- Nnoruka, E.N. Current epidemiology of atopic dermatitis in south-eastern Nigeria. *Int. J. Dermatol.* **2004**, *43*, 739–744. [[CrossRef](#)]
- Lynfield, Y.L. Prominent pruritic periumbilical papules. *Pediatr. Dermatol.* **2000**, *17*, 490. [[CrossRef](#)]
- Allen, H.B.; Jones, N.P.; Bowen, S.E. Lichenoid and other clinical presentations of atopic dermatitis in an inner city practice. *J. Am. Acad. Dermatol.* **2008**, *58*, 503–504. [[CrossRef](#)]
- Hanifin, J.M.; Thurston, M.; Omoto, M.; Cherill, R.; Tofte, S.J.; Graeber, M. The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis. EASI Evaluator Group. *Exp. Dermatol.* **2001**, *10*, 11–18. [[CrossRef](#)]

16. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: The SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. *Dermatology* **1993**, *186*, 23–31. [[CrossRef](#)]
17. Ben-Gashir, M.A.; Hay, R.J. Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts. *Br. J. Dermatol.* **2002**, *147*, 920–925. [[CrossRef](#)]
18. Alexis, A.F.; Sergay, A.B.; Taylor, S.C. Common dermatologic disorders in skin of color: A comparative practice survey. *Cutis* **2007**, *80*, 387–394.
19. Nedoszytko, B.; Reszka, E.; Gutowska-Owsiak, D.; Trzeciak, M.; Lange, M.; Jarczak, J.; Niedozytko, M.; Jablonska, E.; Romantowski, J.; Strapagiel, D.; et al. Genetic and Epigenetic Aspects of Atopic Dermatitis. *Int. J. Mol. Sci.* **2020**, *21*, 6484. [[CrossRef](#)]
20. Barnes, K.C. An update on the genetics of atopic dermatitis: Scratching the surface in 2009. *J. Allergy Clin. Immunol.* **2010**, *125*, 16–29.e11. [[CrossRef](#)]
21. Ortiz, R.A.; Barnes, K.C. Genetics of allergic diseases. *Immunol. Allergy Clin. N. Am.* **2015**, *35*, 19–44. [[CrossRef](#)] [[PubMed](#)]
22. Paternoster, L.; Standl, M.; Waage, J.; Baurecht, H.; Hotze, M.; Strachan, D.P.; Curtin, J.A.; Bonnelykke, K.; Tian, C.; Takahashi, A.; et al. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nat. Genet.* **2015**, *47*, 1449–1456. [[CrossRef](#)] [[PubMed](#)]
23. Ellinghaus, D.; Baurecht, H.; Esparza-Gordillo, J.; Rodriguez, E.; Matanovic, A.; Marenholz, I.; Hubner, N.; Schaarschmidt, H.; Novak, N.; Michel, S.; et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. *Nat. Genet.* **2013**, *45*, 808–812. [[CrossRef](#)] [[PubMed](#)]
24. Liang, Y.; Chang, C.; Lu, Q. The Genetics and Epigenetics of Atopic Dermatitis-Filaggrin and Other Polymorphisms. *Clin. Rev. Allergy Immunol.* **2016**, *51*, 315–328. [[CrossRef](#)] [[PubMed](#)]
25. Hirota, T.; Takahashi, A.; Kubo, M.; Tsunoda, T.; Tomita, K.; Sakashita, M.; Yamada, T.; Fujieda, S.; Tanaka, S.; Doi, S.; et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. *Nat. Genet.* **2012**, *44*, 1222–1226. [[CrossRef](#)]
26. Sun, L.D.; Xiao, F.L.; Li, Y.; Zhou, W.M.; Tang, H.Y.; Tang, X.F.; Zhang, H.; Schaarschmidt, H.; Zuo, X.B.; Foelster-Holst, R.; et al. Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. *Nat. Genet.* **2011**, *43*, 690–694. [[CrossRef](#)]
27. Rodriguez, E.; Baurecht, H.; Herberich, E.; Wagenpfeil, S.; Brown, S.J.; Cordell, H.J.; Irvine, A.D.; Weidinger, S. Meta-analysis of filaggrin polymorphisms in eczema and asthma: Robust risk factors in atopic disease. *J. Allergy Clin. Immunol.* **2009**, *123*, 1361–1370.e1367. [[CrossRef](#)]
28. Torrelo, A. Atopic dermatitis in different skin types. What is to know? *J. Eur. Acad. Dermatol. Venereol.* **2014**, *28* (Suppl. 3), 2–4. [[CrossRef](#)]
29. Park, J.; Jekarl, D.W.; Kim, Y.; Kim, J.; Kim, M.; Park, Y.M. Novel FLG null mutations in Korean patients with atopic dermatitis and comparison of the mutational spectra in Asian populations. *J. Dermatol.* **2015**, *42*, 867–873. [[CrossRef](#)]
30. Brown, S.J.; McLean, W.H. One remarkable molecule: Filaggrin. *J. Investig. Dermatol.* **2012**, *132*, 751–762. [[CrossRef](#)]
31. Drislane, C.; Irvine, A.D. The role of filaggrin in atopic dermatitis and allergic disease. *Ann. Allergy Asthma Immunol.* **2020**, *124*, 36–43. [[CrossRef](#)]
32. Irvine, A.D.; McLean, W.H.; Leung, D.Y. Filaggrin mutations associated with skin and allergic diseases. *N. Engl. J. Med.* **2011**, *365*, 1315–1327. [[CrossRef](#)]
33. Margolis, D.J.; Apter, A.J.; Gupta, J.; Hoffstad, O.; Papadopoulos, M.; Campbell, L.E.; Sandilands, A.; McLean, W.H.; Rebbeck, T.R.; Mitra, N. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. *J. Allergy Clin. Immunol.* **2012**, *130*, 912–917. [[CrossRef](#)]
34. Smith, F.J.; Irvine, A.D.; Terron-Kwiatkowski, A.; Sandilands, A.; Campbell, L.E.; Zhao, Y.; Liao, H.; Evans, A.T.; Goudie, D.R.; Lewis-Jones, S.; et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. *Nat. Genet.* **2006**, *38*, 337–342. [[CrossRef](#)]
35. Thawer-Esmail, F.; Jakasa, I.; Todd, G.; Wen, Y.; Brown, S.J.; Kroboth, K.; Campbell, L.E.; O'Regan, G.M.; McLean, W.H.; Irvine, A.D.; et al. South African amaXhosa patients with atopic dermatitis have decreased levels of filaggrin breakdown products but no loss-of-function mutations in filaggrin. *J. Allergy Clin. Immunol.* **2014**, *133*, 280–282.e281–282. [[CrossRef](#)]
36. Margolis, D.J.; Gupta, J.; Apter, A.J.; Hoffstad, O.; Papadopoulos, M.; Rebbeck, T.R.; Wubbenhorst, B.; Mitra, N. Exome sequencing of filaggrin and related genes in African-American children with atopic dermatitis. *J. Investig. Dermatol.* **2014**, *134*, 2272–2274. [[CrossRef](#)]
37. Fernandez, K.; Asad, S.; Taylan, F.; Wahlgren, C.F.; Bilcha, K.D.; Nordenskjold, M.; Winge, M.C.G.; Bradley, M. Intragenic Copy Number Variation in the Filaggrin Gene in Ethiopian Patients with Atopic Dermatitis. *Pediatr. Dermatol.* **2017**, *34*, e140–e141. [[CrossRef](#)]
38. Polcari, I.; Becker, L.; Stein, S.L.; Smith, M.S.; Paller, A.S. Filaggrin gene mutations in African Americans with both ichthyosis vulgaris and atopic dermatitis. *Pediatr. Dermatol.* **2014**, *31*, 489–492. [[CrossRef](#)]
39. Taylan, F.; Nilsson, D.; Asad, S.; Lieden, A.; Wahlgren, C.F.; Winge, M.C.; Bilcha, K.D.; Nordenskjold, M.; Bradley, M. Whole-exome sequencing of Ethiopian patients with ichthyosis vulgaris and atopic dermatitis. *J. Allergy Clin. Immunol.* **2015**, *136*, 507–509.e519. [[CrossRef](#)]

40. Henry, J.; Toulza, E.; Hsu, C.Y.; Pellerin, L.; Balica, S.; Mazereeuw-Hautier, J.; Paul, C.; Serre, G.; Jonca, N.; Simon, M. Update on the epidermal differentiation complex. *Front. Biosci.* **2012**, *17*, 1517–1532. [[CrossRef](#)]
41. Wu, Z.; Hansmann, B.; Meyer-Hoffert, U.; Glaser, R.; Schroder, J.M. Molecular identification and expression analysis of filaggrin-2, a member of the S100 fused-type protein family. *PLoS ONE* **2009**, *4*, e5227. [[CrossRef](#)] [[PubMed](#)]
42. Margolis, D.J.; Gupta, J.; Apter, A.J.; Ganguly, T.; Hoffstad, O.; Papadopoulos, M.; Rebbeck, T.R.; Mitra, N. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. *J. Allergy Clin. Immunol.* **2014**, *133*, 784–789. [[CrossRef](#)] [[PubMed](#)]
43. Pellerin, L.; Henry, J.; Hsu, C.Y.; Balica, S.; Jean-Decoster, C.; Mechin, M.C.; Hansmann, B.; Rodriguez, E.; Weindinger, S.; Schmitt, A.M.; et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. *J. Allergy Clin. Immunol.* **2013**, *131*, 1094–1102. [[CrossRef](#)] [[PubMed](#)]
44. Marenholz, I.; Rivera, V.A.; Esparza-Gordillo, J.; Bauerfeind, A.; Lee-Kirsch, M.A.; Ciechanowicz, A.; Kurek, M.; Piskackova, T.; Macek, M.; Lee, Y.A. Association screening in the Epidermal Differentiation Complex (EDC) identifies an SPRR3 repeat number variant as a risk factor for eczema. *J. Investig. Dermatol.* **2011**, *131*, 1644–1649. [[CrossRef](#)]
45. Asad, S.; Winge, M.C.; Wahlgren, C.F.; Bilcha, K.D.; Nordenskjold, M.; Taylan, F.; Bradley, M. The tight junction gene Claudin-1 is associated with atopic dermatitis among Ethiopians. *J. Eur. Acad. Dermatol. Venereol.* **2016**, *30*, 1939–1941. [[CrossRef](#)]
46. Kato, A.; Fukai, K.; Oiso, N.; Hosomi, N.; Murakami, T.; Ishii, M. Association of SPINK5 gene polymorphisms with atopic dermatitis in the Japanese population. *Br. J. Dermatol.* **2003**, *148*, 665–669. [[CrossRef](#)]
47. Nishio, Y.; Noguchi, E.; Shibasaki, M.; Kamioka, M.; Ichikawa, E.; Ichikawa, K.; Umebayashi, Y.; Otsuka, F.; Arinami, T. Association between polymorphisms in the SPINK5 gene and atopic dermatitis in the Japanese. *Genes Immun.* **2003**, *4*, 515–517. [[CrossRef](#)]
48. Lan, C.C.; Tu, H.P.; Wu, C.S.; Ko, Y.C.; Yu, H.S.; Lu, Y.W.; Li, W.C.; Chen, Y.C.; Chen, G.S. Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population. *Exp. Dermatol.* **2011**, *20*, 975–979. [[CrossRef](#)]
49. Zhao, L.P.; Di, Z.; Zhang, L.; Wang, L.; Ma, L.; Lv, Y.; Hong, Y.; Wei, H.; Chen, H.D.; Gao, X.H. Association of SPINK5 gene polymorphisms with atopic dermatitis in Northeast China. *J. Eur. Acad. Dermatol. Venereol.* **2012**, *26*, 572–577. [[CrossRef](#)]
50. Kim, B.E.; Leung, D.Y.; Boguniewicz, M.; Howell, M.D. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. *Clin. Immunol.* **2008**, *126*, 332–337. [[CrossRef](#)]
51. Sokolowska-Wojdylo, M.; Glen, J.; Zablotna, M.; Rebala, K.; Sikorska, M.; Florek, A.; Trzeciak, M.; Baranska-Rybak, W.; Malek, M.; Nedoszytko, B. Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis. *J. Eur. Acad. Dermatol. Venereol.* **2013**, *27*, 662–664. [[CrossRef](#)]
52. Shang, H.; Cao, X.L.; Wan, Y.J.; Meng, J.; Guo, L.H. IL-4 Gene Polymorphism May Contribute to an Increased Risk of Atopic Dermatitis in Children. *Dis. Markers* **2016**, *2016*, 1021942. [[CrossRef](#)]
53. Oiso, N.; Fukai, K.; Ishii, M. Interleukin 4 receptor alpha chain polymorphism Gln551Arg is associated with adult atopic dermatitis in Japan. *Br. J. Dermatol.* **2000**, *142*, 1003–1006. [[CrossRef](#)]
54. Hussein, Y.M.; Shalaby, S.M.; Nassar, A.; Alzahrani, S.S.; Alharbi, A.S.; Nouh, M. Association between genes encoding components of the IL-4/IL-4 receptor pathway and dermatitis in children. *Gene* **2014**, *545*, 276–281. [[CrossRef](#)]
55. Tsunemi, Y.; Saeki, H.; Nakamura, K.; Sekiya, T.; Hirai, K.; Kakinuma, T.; Fujita, H.; Asano, N.; Tanida, Y.; Wakugawa, M.; et al. Interleukin-13 gene polymorphism G4257A is associated with atopic dermatitis in Japanese patients. *J. Dermatol. Sci.* **2002**, *30*, 100–107. [[CrossRef](#)]
56. Kawashima, T.; Noguchi, E.; Arinami, T.; Yamakawa-Kobayashi, K.; Nakagawa, H.; Otsuka, F.; Hamaguchi, H. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. *J. Med. Genet.* **1998**, *35*, 502–504. [[CrossRef](#)]
57. Jiang, X.Y.; Zhao, J.H.; Yu, C.X.; Fang, L.; Zheng, X.D.; Yin, X.Y.; Wu, Y.Y.; Tang, X.F.; Zhou, F.S.; Zhang, X.J.; et al. Association analyses identify two susceptibility loci 5q31 and 5q22.1 for atopic dermatitis in Chinese Han population. *Asian Pac. J. Allergy Immunol.* **2017**, *35*, 196–202. [[CrossRef](#)]
58. Caggana, M.; Walker, K.; Reilly, A.A.; Conroy, J.M.; Duva, S.; Walsh, A.C. Population-based studies reveal differences in the allelic frequencies of two functionally significant human interleukin-4 receptor polymorphisms in several ethnic groups. *Genet. Med.* **1999**, *1*, 267–271. [[CrossRef](#)]
59. Yang, B.; Wilkie, H.; Das, M.; Timilshina, M.; Bainter, W.; Woods, B.; Daya, M.; Boorgula, M.P.; Mathias, R.A.; Lai, P.; et al. The IL-4Ralpha Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in mice. *J. Allergy Clin. Immunol.* **2023**, *in press*. [[CrossRef](#)]
60. Gao, P.S.; Rafaels, N.M.; Mu, D.; Hand, T.; Murray, T.; Boguniewicz, M.; Hata, T.; Schneider, L.; Hanifin, J.M.; Gallo, R.L.; et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. *J. Allergy Clin. Immunol.* **2010**, *125*, 1403–1407.e1404. [[CrossRef](#)]
61. Esaki, H.; Ewald, D.A.; Ungar, B.; Rozenblit, M.; Zheng, X.; Xu, H.; Estrada, Y.D.; Peng, X.; Mitsui, H.; Litman, T.; et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. *J. Allergy Clin. Immunol.* **2015**, *135*, 153–163. [[CrossRef](#)] [[PubMed](#)]
62. Lee, Y.L.; Yen, J.J.; Hsu, L.C.; Kuo, N.W.; Su, M.W.; Yang, M.F.; Hsiao, Y.P.; Wang, I.J.; Liu, F.T. Association of STAT6 genetic variants with childhood atopic dermatitis in Taiwanese population. *J. Dermatol. Sci.* **2015**, *79*, 222–228. [[CrossRef](#)]

63. Gao, P.S.; Leung, D.Y.; Rafaels, N.M.; Boguniewicz, M.; Hand, T.; Gao, L.; Hata, T.R.; Schneider, L.C.; Hanifin, J.M.; Beaty, T.H.; et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. *J. Investig. Dermatol.* **2012**, *132*, 650–657. [[CrossRef](#)] [[PubMed](#)]
64. Margolis, D.J.; Kim, B.; Apter, A.J.; Gupta, J.; Hoffstad, O.; Papadopoulos, M.; Mitra, N. Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis. *JAMA Dermatol.* **2014**, *150*, 254–259. [[CrossRef](#)] [[PubMed](#)]
65. Potaczek, D.P.; Nastalek, M.; Okumura, K.; Wojas-Pelc, A.; Undas, A.; Nishiyama, C. An association of TLR2-16934A >T polymorphism and severity/phenotype of atopic dermatitis. *J. Eur. Acad. Dermatol. Venereol.* **2011**, *25*, 715–721. [[CrossRef](#)] [[PubMed](#)]
66. Niwa, Y.; Potaczek, D.P.; Kanada, S.; Takagi, A.; Shimokawa, N.; Ito, T.; Mitsuishi, K.; Okubo, Y.; Tajima, M.; Hobo, A.; et al. FcεpsilonRIα gene (FCER1A) promoter polymorphisms and total serum IgE levels in Japanese atopic dermatitis patients. *Int. J. Immunogenet.* **2010**, *37*, 139–141. [[CrossRef](#)]
67. Prado-Montes de Oca, E.; Garcia-Vargas, A.; Lozano-Inocencio, R.; Gallegos-Arreola, M.P.; Sandoval-Ramirez, L.; Davalos-Rodriguez, N.O.; Figuera, L.E. Association of beta-defensin 1 single nucleotide polymorphisms with atopic dermatitis. *Int. Arch. Allergy Immunol.* **2007**, *142*, 211–218. [[CrossRef](#)]
68. Kim, E.; Lee, J.E.; Namkung, J.H.; Kim, P.S.; Kim, S.; Shin, E.S.; Cho, E.Y.; Yang, J.M. Single nucleotide polymorphisms and the haplotype in the DEFB1 gene are associated with atopic dermatitis in a Korean population. *J. Dermatol. Sci.* **2009**, *54*, 25–30. [[CrossRef](#)]
69. Segat, L.; Guimaraes, R.L.; Brandao, L.A.; Rocha, C.R.; Zanin, V.; Trevisiol, C.; de Lima Filho, J.L.; Crovella, S. Beta defensin-1 gene (DEFB1) polymorphisms are not associated with atopic dermatitis in children and adolescents from northeast Brazil (Recife, Pernambuco). *Int. J. Dermatol.* **2010**, *49*, 653–657. [[CrossRef](#)]
70. Namkung, J.H.; Lee, J.E.; Kim, E.; Kim, S.; Kim, S.; Shin, E.S.; Cho, E.Y.; Yang, J.M. Association of single nucleotide polymorphisms in the IL-12 (IL-12A and B) and IL-12 receptor (IL-12Rβ1 and β2) genes and gene-gene interactions with atopic dermatitis in Koreans. *J. Dermatol. Sci.* **2010**, *57*, 199–206. [[CrossRef](#)]
71. Paller, A.S.; Kong, H.H.; Seed, P.; Naik, S.; Schar Schmidt, T.C.; Gallo, R.L.; Luger, T.; Irvine, A.D. The microbiome in patients with atopic dermatitis. *J. Allergy Clin. Immunol.* **2019**, *143*, 26–35. [[CrossRef](#)]
72. Leyden, J.J.; Marples, R.R.; Kligman, A.M. Staphylococcus aureus in the lesions of atopic dermatitis. *Br. J. Dermatol.* **1974**, *90*, 525–530. [[CrossRef](#)]
73. Tauber, M.; Balica, S.; Hsu, C.Y.; Jean-Decoster, C.; Lauze, C.; Redoules, D.; Viode, C.; Schmitt, A.M.; Serre, G.; Simon, M.; et al. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. *J. Allergy Clin. Immunol.* **2016**, *137*, 1272–1274.e1273. [[CrossRef](#)]
74. Kong, H.H.; Oh, J.; Deming, C.; Conlan, S.; Grice, E.A.; Beatson, M.A.; Nomicos, E.; Polley, E.C.; Komarow, H.D.; Program, N.C.S.; et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res.* **2012**, *22*, 850–859. [[CrossRef](#)]
75. Meylan, P.; Lang, C.; Mermoud, S.; Johannsen, A.; Norrenberg, S.; Hohl, D.; Vial, Y.; Prod'homme, G.; Greub, G.; Kyriakou, M.; et al. Skin Colonization by Staphylococcus aureus Precedes the Clinical Diagnosis of Atopic Dermatitis in Infancy. *J. Investig. Dermatol.* **2017**, *137*, 2497–2504. [[CrossRef](#)]
76. Merriman, J.A.; Mueller, E.A.; Cahill, M.P.; Beck, L.A.; Paller, A.S.; Hanifin, J.M.; Ong, P.Y.; Schneider, L.; Babineau, D.C.; David, G.; et al. Temporal and Racial Differences Associated with Atopic Dermatitis Staphylococcus aureus and Encoded Virulence Factors. *mSphere* **2016**, *1*, e00295-16. [[CrossRef](#)]
77. Sun, R.; Chana, S.M.; Hawes, E.; Hendricks, P.S.; Cropsey, K.L.; Gaggar, A.; Scarinci, I.C. Examining Racial/Ethnic and Income Disparities on Tobacco Product Use Among US Adults Within Wave 5 of the PATH Study. *J. Addict. Med.* **2022**. [[CrossRef](#)] [[PubMed](#)]
78. Rahman, J.; Scragg, R. Factors associated with self-reported sun exposure in a multi-ethnic community sample from New Zealand. *J. Steroid Biochem. Mol. Biol.* **2022**, *221*, 106131. [[CrossRef](#)]
79. Jamerson, T.A.; Li, Q.; Sreekandarajan, S.; Budunova, I.V.; He, Z.; Kang, J.; Gudjonsson, J.E.; Patrick, M.T.; Tsoi, L.C. Roles Played by Stress-Induced Pathways in Driving Ethnic Heterogeneity for Inflammatory Skin Diseases. *Front. Immunol.* **2022**, *13*, 845655. [[CrossRef](#)]
80. Peek, M.E.; Wagner, J.; Tang, H.; Baker, D.C.; Chin, M.H. Self-reported racial discrimination in health care and diabetes outcomes. *Med. Care* **2011**, *49*, 618–625. [[CrossRef](#)]
81. Verzeaux, L.; Vyumvuhore, R.; Boudier, D.; Le Guillou, M.; Bordes, S.; Essendoubi, M.; Manfait, M.; Closs, B. Atopic skin: In vivo Raman identification of global molecular signature, a comparative study with healthy skin. *Exp. Dermatol.* **2018**, *27*, 403–408. [[CrossRef](#)] [[PubMed](#)]
82. Vulcano, M.; Albanesi, C.; Stoppacciaro, A.; Bagnati, R.; D'Amico, G.; Struyf, S.; Transidico, P.; Bonocchi, R.; Del Prete, A.; Allavena, P.; et al. Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. *Eur. J. Immunol.* **2001**, *31*, 812–822. [[CrossRef](#)] [[PubMed](#)]
83. Onoue, A.; Kabashima, K.; Kobayashi, M.; Mori, T.; Tokura, Y. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. *Exp. Dermatol.* **2009**, *18*, 1036–1043. [[CrossRef](#)] [[PubMed](#)]

84. Soumelis, V.; Reche, P.A.; Kanzler, H.; Yuan, W.; Edward, G.; Homey, B.; Gilliet, M.; Ho, S.; Antonenko, S.; Lauerma, A.; et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat. Immunol.* **2002**, *3*, 673–680. [[CrossRef](#)] [[PubMed](#)]
85. Ito, T.; Wang, Y.H.; Duramad, O.; Hori, T.; Delespesse, G.J.; Watanabe, N.; Qin, F.X.; Yao, Z.; Cao, W.; Liu, Y.J. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. *J. Exp. Med.* **2005**, *202*, 1213–1223. [[CrossRef](#)]
86. Salimi, M.; Barlow, J.L.; Saunders, S.P.; Xue, L.; Gutowska-Owsiak, D.; Wang, X.; Huang, L.C.; Johnson, D.; Scanlon, S.T.; McKenzie, A.N.; et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. *J. Exp. Med.* **2013**, *210*, 2939–2950. [[CrossRef](#)]
87. Mei-Yen Yong, A.; Tay, Y.K. Atopic Dermatitis: Racial and Ethnic Differences. *Dermatol. Clin.* **2017**, *35*, 395–402. [[CrossRef](#)]
88. Yin, L.; Coelho, S.G.; Ebsen, D.; Smuda, C.; Mahns, A.; Miller, S.A.; Beer, J.Z.; Kolbe, L.; Hearing, V.J. Epidermal gene expression and ethnic pigmentation variations among individuals of Asian, European and African ancestry. *Exp. Dermatol.* **2014**, *23*, 731–735. [[CrossRef](#)]
89. Kim, J.; Ahn, K. Atopic dermatitis endotypes: Knowledge for personalized medicine. *Curr. Opin. Allergy Clin. Immunol.* **2022**, *22*, 153–159. [[CrossRef](#)]
90. Chan, T.C.; Sanyal, R.D.; Pavel, A.B.; Glickman, J.; Zheng, X.; Xu, H.; Cho, Y.T.; Tsai, T.F.; Wen, H.C.; Peng, X.; et al. Atopic dermatitis in Chinese patients shows T(H)2/T(H)17 skewing with psoriasiform features. *J. Allergy Clin. Immunol.* **2018**, *142*, 1013–1017. [[CrossRef](#)]
91. Wen, H.C.; Czarnowicki, T.; Noda, S.; Malik, K.; Pavel, A.B.; Nakajima, S.; Honda, T.; Shin, J.U.; Lee, H.; Chou, M.; et al. Serum from Asian patients with atopic dermatitis is characterized by T(H)2/T(H)22 activation, which is highly correlated with nonlesional skin measures. *J. Allergy Clin. Immunol.* **2018**, *142*, 324–328.e311. [[CrossRef](#)]
92. Sanyal, R.D.; Pavel, A.B.; Glickman, J.; Chan, T.C.; Zheng, X.; Zhang, N.; Cueto, I.; Peng, X.; Estrada, Y.; Fuentes-Duculan, J.; et al. Atopic dermatitis in African American patients is T(H)2/T(H)22-skewed with T(H)1/T(H)17 attenuation. *Ann. Allergy Asthma Immunol.* **2019**, *122*, 99–110.e116. [[CrossRef](#)]
93. Eichenfield, L.F.; Ahluwalia, J.; Waldman, A.; Borok, J.; Udkoff, J.; Boguniewicz, M. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines. *J. Allergy Clin. Immunol.* **2017**, *139*, S49–S57. [[CrossRef](#)]
94. Wollenberg, A.; Kinberger, M.; Arents, B.; Aszodi, N.; Avila Valle, G.; Barbarot, S.; Bieber, T.; Brough, H.A.; Calzavara Pinton, P.; Christen-Zach, S.; et al. European guideline (EuroGuiDerm) on atopic eczema-part II: Non-systemic treatments and treatment recommendations for special AE patient populations. *J. Eur. Acad. Dermatol. Venereol.* **2022**, *36*, 1904–1926. [[CrossRef](#)]
95. Wollenberg, A.; Kinberger, M.; Arents, B.; Aszodi, N.; Avila Valle, G.; Barbarot, S.; Bieber, T.; Brough, H.A.; Calzavara Pinton, P.; Christen-Zach, S.; et al. European guideline (EuroGuiDerm) on atopic eczema: Part I-systemic therapy. *J. Eur. Acad. Dermatol. Venereol.* **2022**, *36*, 1409–1431. [[CrossRef](#)]
96. Silverberg, J.I.; Gelfand, J.M.; Margolis, D.J.; Boguniewicz, M.; Fonacier, L.; Grayson, M.H.; Simpson, E.L.; Ong, P.Y.; Chiesa Fuxench, Z.C. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. *Ann. Allergy Asthma Immunol.* **2018**, *121*, 340–347. [[CrossRef](#)]
97. Eichenfield, L.F.; Lucky, A.W.; Langley, R.G.; Lynde, C.; Kaufmann, R.; Todd, G.; Lindsley, L.; Barbier, N.; Felser, J.M. Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: The effects of ethnic origin and baseline disease severity on treatment outcome. *Int. J. Dermatol.* **2005**, *44*, 70–75. [[CrossRef](#)]
98. Kim, K.H.; Kono, T. Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas. *Int. J. Dermatol.* **2011**, *50*, 1153–1161. [[CrossRef](#)]
99. Mok, Z.R.; Koh, M.J.; Chong, W.S. Is phototherapy useful in the treatment of atopic dermatitis in asian children? A 5-year report from singapore. *Pediatr. Dermatol.* **2014**, *31*, 698–702. [[CrossRef](#)]
100. Syed, Z.U.; Hamzavi, I.H. Role of phototherapy in patients with skin of color. *Semin. Cutan. Med. Surg* **2011**, *30*, 184–189. [[CrossRef](#)]
101. Syed, Z.U.; Hamzavi, I.H. Photomedicine and phototherapy considerations for patients with skin of color. *Photodermatol. Photoimmunol. Photomed.* **2011**, *27*, 10–16. [[CrossRef](#)] [[PubMed](#)]
102. Jacobe, H.T.; Cayce, R.; Nguyen, J. UVA1 phototherapy is effective in darker skin: A review of 101 patients of Fitzpatrick skin types I-V. *Br. J. Dermatol.* **2008**, *159*, 691–696. [[CrossRef](#)] [[PubMed](#)]
103. De Souza, B.M.A. Atopic Dermatitis in Patients with Skin of Color. *Dermatologist*. 2019. Available online: <https://www.hmpgloballearningnetwork.com/site/thederm/nea-approved-features/atopic-dermatitis-patients-skin-color> (accessed on 12 February 2023).
104. Seegraber, M.; Srour, J.; Walter, A.; Knop, M.; Wollenberg, A. Dupilumab for treatment of atopic dermatitis. *Expert Rev. Clin. Pharmacol.* **2018**, *11*, 467–474. [[CrossRef](#)] [[PubMed](#)]
105. Beck, L.A.; Thaci, D.; Hamilton, J.D.; Graham, N.M.; Bieber, T.; Rocklin, R.; Ming, J.E.; Ren, H.; Kao, R.; Simpson, E.; et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N. Engl. J. Med.* **2014**, *371*, 130–139. [[CrossRef](#)] [[PubMed](#)]

106. Simpson, E.L.; Bieber, T.; Guttman-Yassky, E.; Beck, L.A.; Blauvelt, A.; Cork, M.J.; Silverberg, J.I.; Deleuran, M.; Kataoka, Y.; Lacour, J.P.; et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N. Engl. J. Med.* **2016**, *375*, 2335–2348. [[CrossRef](#)]
107. Blauvelt, A.; de Bruin-Weller, M.; Gooderham, M.; Cather, J.C.; Weisman, J.; Pariser, D.; Simpson, E.L.; Papp, K.A.; Hong, H.C.; Rubel, D.; et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet* **2017**, *389*, 2287–2303. [[CrossRef](#)]
108. Alexis, A.F.; Rendon, M.; Silverberg, J.I.; Pariser, D.M.; Lockshin, B.; Griffiths, C.E.; Weisman, J.; Wollenberg, A.; Chen, Z.; Davis, J.D.; et al. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. *J. Drugs Dermatol.* **2019**, *18*, 804–813.
109. EMA Approval of Tralokinumab (Adtralza) for the Treatment of Atopic Dermatitis. Published June 2021. Available online: https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf (accessed on 12 February 2023).
110. EMA Approval of Upadacitinib (Rinvoq) for the Treatment of Atopic Dermatitis. Published May 2022. Available online: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-opinion-rinvoq-x-12-g_en.pdf (accessed on 12 February 2023).
111. EMA Approval of Abrocitinib (Cibinqo) for the Treatment of Atopic Dermatitis. Published December 2021. Available online: https://www.ema.europa.eu/en/documents/product-information/cibinqo-epar-product-information_en.pdf (accessed on 12 February 2023).
112. Wollenberg, A.; Blauvelt, A.; Guttman-Yassky, E.; Worm, M.; Lynde, C.; Lacour, J.P.; Spelman, L.; Katoh, N.; Saeki, H.; Poulin, Y.; et al. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). *Br. J. Dermatol.* **2021**, *184*, 437–449. [[CrossRef](#)]
113. Silverberg, J.I.; Toth, D.; Bieber, T.; Alexis, A.F.; Elewski, B.E.; Pink, A.E.; Hijnen, D.; Jensen, T.N.; Bang, B.; Olsen, C.K.; et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. *Br. J. Dermatol.* **2021**, *184*, 450–463. [[CrossRef](#)]
114. Blauvelt, A.; Gooderham, M.; Bhatia, N.; Langle, R.G.; Schneider, S.; Zoidis, J.; Kurbasic, A.; Armstrong, A.; Silverberg, J.I. Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3. *Dermatol. Ther.* **2022**, *12*, 2499–2516. [[CrossRef](#)]
115. Irvine, A.D.; McLean, W.H. Breaking the (un)sound barrier: Filaggrin is a major gene for atopic dermatitis. *J. Investig. Dermatol.* **2006**, *126*, 1200–1202. [[CrossRef](#)]
116. Thyssen, J.P.; Thuesen, B.; Huth, C.; Standl, M.; Carson, C.G.; Heinrich, J.; Kramer, U.; Kratzsch, J.; Berg, N.D.; Menne, T.; et al. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations. *J. Allergy Clin. Immunol.* **2012**, *130*, 1204–1207.e1202. [[CrossRef](#)]
117. Takeshita, J.; Gupta, J.; Zhu, Y.; Berna, R.; Chiesa Fuxench, Z.C.; Margolis, D.J. Atopic dermatitis and the atopic march: Considering racial and ethnic diversity in atopic disease progression. *J. Allergy Clin. Immunol.* **2022**, *149*, 1590–1591. [[CrossRef](#)]
118. Biagini, J.M.; Kroner, J.W.; Baatyrbek Kyzy, A.; Gonzales, A.; He, H.; Stevens, M.; Grashel, B.; Spagna, D.; Paul, S.; Patel, R.; et al. Longitudinal atopic dermatitis endotypes: An atopic march paradigm that includes Black children. *J. Allergy Clin. Immunol.* **2022**, *149*, 1702–1710.e1704. [[CrossRef](#)]
119. Ungar, B.; Pavel, A.B.; Li, R.; Kimmel, G.; Nia, J.; Hashim, P.; Kim, H.J.; Chima, M.; Vekaria, A.S.; Estrada, Y.; et al. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. *J. Allergy Clin. Immunol.* **2021**, *147*, 394–397. [[CrossRef](#)]
120. Hamilton, J.D.; Suarez-Farinas, M.; Dhingra, N.; Cardinale, I.; Li, X.; Kostic, A.; Ming, J.E.; Radin, A.R.; Krueger, J.G.; Graham, N.; et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. *J. Allergy Clin. Immunol.* **2014**, *134*, 1293–1300. [[CrossRef](#)]
121. Howell, M.D.; Fitzsimons, C.; Smith, P.A. JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease. *Ann. Allergy Asthma Immunol.* **2018**, *120*, 367–375. [[CrossRef](#)]
122. Charrow, A.; Xia, F.D.; Joyce, C.; Mostaghimi, A. Diversity in Dermatology Clinical Trials: A Systematic Review. *JAMA Dermatol.* **2017**, *153*, 193–198. [[CrossRef](#)]
123. Bhattacharya, T.; Silverberg, J.I. Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States. *JAMA Dermatol.* **2014**, *150*, 1232–1234. [[CrossRef](#)]
124. Hirano, S.A.; Murray, S.B.; Harvey, V.M. Reporting, representation, and subgroup analysis of race and ethnicity in published clinical trials of atopic dermatitis in the United States between 2000 and 2009. *Pediatr. Dermatol.* **2012**, *29*, 749–755. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.